CYDY - CytoDyn: Bulls And Bears Need To Come To Terms On COVID-19 Efforts
- CytoDyn's COVID-19 efforts continue to be a battleground for bulls and bears. I believe that the bulls and bears need to come to terms with CytoDyn's programs and leronlimab's prospects.
- The company has moved beyond the U.S. FDA and is looking to conduct trials in other countries. However, the U.S. FDA decided to make a public statement about leronlimab.
- CytoDyn announced that Chiral Pharma made their first purchase order for leronlimab to be used for COVID-19 CSPs in the Philippines. CytoDyn will finally be collecting some revenue.
- I provide my opinions on the latest developments and discuss my augmented plans for CYDY.
For further details see:
CytoDyn: Bulls And Bears Need To Come To Terms On COVID-19 Efforts